Talk:Ranbaxy Laboratories
This article is rated C-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||||||||||||||||||||
|
Acquisition
[edit]Expand the section on the acquisition please. Laxstar5 (talk) 16:27, 14 June 2008 (UTC)
Largest
[edit]The article currently describes Ranbaxy as India's largest pharmaceutical company, while the article on Dr. Reddy's Laboratories describes Dr. Reddy's Laboratories as India’s biggest pharmaceutical company. Does this make any sense? Is this company the largest while the other is the biggest? 85.228.101.208 (talk) 13:11, 12 December 2008 (UTC)
US FDA says Ranbaxy plant falsified data
[edit]WASHINGTON, Feb 25 (Reuters) - A plant owned by Indian generic drugmaker Ranbaxy Laboratories (RANB.BO) falsified data and test results in approved and pending drug applications, U.S. regulators said on Wednesday. http://www.reuters.com/article/governmentFilingsNews/idUSN2549047720090225 Mullins99 (talk) 20:58, 25 February 2009 (UTC)
This company has a history of data falsification. 30 drugs marketed by Ranbaxy were banned from the US market in 2008. See article: http://www.yourlawyer.com/articles/read/15151 — Preceding unsigned comment added by 188.27.129.31 (talk) 08:27, 8 March 2012 (UTC)
This is pretty horrifying and should be used in the article. 70.36.142.149 (talk) 05:02, 17 October 2014 (UTC)
- Yes, it is. However, it is already covered in the article. Your reference is linked as well. Alfie↑↓© 21:22, 17 October 2014 (UTC)
Shocking POV
[edit]The "reasons for merger" section is (at the most basic level) a POV/opinion piece that has no business in this project. It's entire purpose appears to be to push a particular POV. It's full of opinion, flowery language and hyperbole, and the fact that it has a "conclusions" sub-section suggests it is a form of OR completely unsuited to this project. It also talks in CYRSTALBALL terms about what's going to happen in the future - in a fashion again totally unsuited to this project. It may be that some of it can be salvaged, but - if not - it should be culled completely; Save for the one or two cited facts in the "intro" about when and how the M&A came about. Guliolopez (talk) 16:29, 7 May 2009 (UTC)
- OK. Given that there were no alternative suggestions, I culled all the POV/OR content. (And noted in the process that it appeared to be a largely a copy and paste of this) And therefore broke a further tenet. Guliolopez (talk) 15:09, 19 May 2009 (UTC)
Emerging from issues
[edit]I just undid this edit which removed a new paragraph about Ranbaxy beginning to emerge from a troubled time in its history. While true that the paragraph is not an "issue," the paragraph is relevant to Ranbaxy's history. Perhaps the article is not structured well to chronicle the company's history. I would recommend against removing properly-sourced content. -- ke4roh (talk) 14:44, 6 November 2014 (UTC)
Merger with Sun Pharma?
[edit]For whatever it is worth, I went to their web site and got redirected to that of Sun Pharma. Limit-theorem (talk) 17:34, 20 April 2015 (UTC)
External links modified
[edit]Hello fellow Wikipedians,
I have just modified 4 external links on Ranbaxy Laboratories. Please take a moment to review my edit. If you have any questions, or need the bot to ignore the links, or the page altogether, please visit this simple FaQ for additional information. I made the following changes:
- Added archive https://web.archive.org/web/20150502221904/http://www.trustadvisory.info/allindia_2014.html to http://www.trustadvisory.info/allindia_2014.html
- Added archive https://archive.is/20130131175140/http://www.pharmaexhibition.com/Exhibit/Ranbaxy-Laboratories-Limited/India/Home to http://www.pharmaexhibition.com/Exhibit/Ranbaxy-Laboratories-Limited/India/Home
- Added archive https://web.archive.org/web/20130923030519/http://www.niticentral.com/2013/09/18/ranbaxy-import-ban-usfda-found-suspected-hair-oil-in-tablets-134445.html to http://www.niticentral.com/2013/09/18/ranbaxy-import-ban-usfda-found-suspected-hair-oil-in-tablets-134445.html
- Added archive https://web.archive.org/web/20050916092549/http://www.ranbaxy.com/ to http://www.ranbaxy.com/
When you have finished reviewing my changes, you may follow the instructions on the template below to fix any issues with the URLs.
This message was posted before February 2018. After February 2018, "External links modified" talk page sections are no longer generated or monitored by InternetArchiveBot. No special action is required regarding these talk page notices, other than regular verification using the archive tool instructions below. Editors have permission to delete these "External links modified" talk page sections if they want to de-clutter talk pages, but see the RfC before doing mass systematic removals. This message is updated dynamically through the template {{source check}}
(last update: 5 June 2024).
- If you have discovered URLs which were erroneously considered dead by the bot, you can report them with this tool.
- If you found an error with any archives or the URLs themselves, you can fix them with this tool.
Cheers.—InternetArchiveBot (Report bug) 21:44, 10 December 2017 (UTC)
Controversies largely underplayed
[edit]I just listened to a 2h30 audio interview of Katherine Eban, the author of "Bottle of Lies", a new book about Ranbaxy's scandal.
- Book here, https://www.amazon.com/Bottle-Lies-Inside-Story-Generic/dp/0062338781
- Audio interview here https://peterattiamd.com/katherineeban/.
The criminal nature and the scale of Ranbaxy's fraudulent activities are clearly underplayed in this article, through the use of euphemisms, distractions, and the lack of relevant information. Ranbaxy was way more than simply "laden with controversy" as currently stated in the introduction, and the Controversies section currently does not make it clear that the company's "whose business model was completely dependent on falsifying data in their drug applications to the FDA" (in the words of Katherine Eban's interviewer). What can be done to fix this? Dragice (talk) 10:36, 26 September 2019 (UTC)
- Having read "Bottle of Lies" in August, I agree with your statements above.--Dthomsen8 (talk) 03:05, 27 November 2019 (UTC)
- I added a couple sentences about the book, but I'm not willing to rewrite the entire section myself based on the single source that I read. Vox Sciurorum (talk) 19:06, 8 December 2019 (UTC)
I was surprised to read the above comments, as my reaction to the tone of the section was very different. It seems to mostly describe a bustup with the FDA, and reads as if written by someone with an axe to grind. US big pharma is very, very hostile to generic drug manufacturers, particularly Indian ones, and this attitude is shared to a greater or lesser extent by the entire US health system. The rest of the world seems perfectly happy to use generic drugs, and doctors there are encouraged (and sometimes required) to prescribe generically. --Ef80 (talk) 14:10, 24 September 2021 (UTC)
A Commons file used on this page or its Wikidata item has been nominated for speedy deletion
[edit]The following Wikimedia Commons file used on this page or its Wikidata item has been nominated for speedy deletion:
You can see the reason for deletion at the file description page linked above. —Community Tech bot (talk) 15:37, 4 April 2022 (UTC)
- C-Class company articles
- High-importance company articles
- WikiProject Companies articles
- C-Class India articles
- Low-importance India articles
- C-Class India articles of Low-importance
- WikiProject India articles
- C-Class pharmacology articles
- Low-importance pharmacology articles
- WikiProject Pharmacology articles